FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to keratin variants. Invention provides therapeutic use of keratin, having efficacy in reducing body temperature rise in fever model in SD rats and prolonging the latency of seizures in class III epilepsy in mice, expectorant action in the method with releasing phenol red in mice, antitussive action in a method for stimulating cough using an aqueous solution of ammonia in mice and a tendency to reduce the number of writhing in mice and the potential for analgesic action in acetic acid-induced writhing in ICR mice.
EFFECT: invention can be used in medicine to produce a drug having antipyretic, analgesic, antitussive, expectorant, anticonvulsant and antiepileptic action.
10 cl, 3 dwg, 9 tbl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
KERATIN BD-6, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2825993C1 |
KERATIN BD-11, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2825992C1 |
KERATIN BD-3, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2815384C1 |
KERATIN BD-10, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2823655C1 |
KERATIN BD-1, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2825994C1 |
KERATIN BD-4, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF | 2020 |
|
RU2824893C1 |
ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
Authors
Dates
2024-09-02—Published
2020-10-28—Filed